086060 — Genebiotech Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩34bn
- KR₩27bn
- KR₩79bn
- 71
- 88
- 15
- 63
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 25,039 | 24,137 | 14,290 | 12,790 | 19,016 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 7,912 | 6,899 | 10,371 | 14,302 | 11,818 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 43,862 | 45,470 | 42,175 | 46,269 | 49,281 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 18,769 | 12,910 | 14,900 | 14,615 | 14,159 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 67,933 | 62,085 | 60,368 | 64,041 | 66,017 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 9,942 | 13,065 | 14,139 | 15,920 | 14,513 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 21,004 | 17,042 | 16,423 | 18,315 | 17,712 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 46,929 | 45,043 | 43,945 | 45,726 | 48,305 |
Total Liabilities & Shareholders' Equity | 67,933 | 62,085 | 60,368 | 64,041 | 66,017 |
Total Common Shares Outstanding |